Formulation and In-vitro Evaluation of Rivastigmine Transdermal Patches

Abstract

Rivastigmine is a acetylcholinesterase inhibitor used for the treatment of mild to moderate Alzheimer's disease and Parkinson's. In present study transdermal drug delivery of Rivastigmine   was developed to overcome the first pass metabolism and to reduce frequency of dosing compared to oral route. Oral drug delivery system has various drawbacks like poor bioavailability due to hepatic metabolism (first pass) and the tendency to produce rapid blood level spikes (both high and low), leading to a need for high and/or frequent dosing, which can be both cost prohibitive and inconvenient. Matrix type of transdermal patches was developed by using Guar gum (mg), Carrageenan gum (mg), Eudragit L 100 Transdermal patches were prepared by employing solvent casting method. Drug excipient compatibility studies were carried out by using FTIR, and it was observed that there were no interactions. Formulations were prepared with the varying concentrations polymers ranging from F1-F9, and all the formulations were evaluated for various physical parameters Physical appearance, Flatness, Weight variation, Thickness, Folding endurance, Drug content, Moisture uptake, Moisture content and Swelling study and all the results were found to be were found to be with in the pharmacopeial limits, in-vitro drug release studies by using dialysis membrane. Among all the 9 formulations F6 formulation which contain Carrageenan gum 40mg had shown 98.43% cumulative drug release within 12 hours.